🔴 GT Biopharma is trading 7% down today after Nasdaq disclosed 1-for-25 reverse split

GT Biopharma is trading 7.05% down now at $0.23 after Nasdaq disclosed its 1-for-25 reverse stock split, effective September 8, 2026.

• The transaction will consolidate every 25 shares into one and change the company’s CUSIP, highlighting listing-compliance and capital-structure pressures.
• Shares also fell 10.81% on September 3, suggesting continued selling ahead of the split.
• Nasdaq confirmed the corporate action on September 3, 2026.